Mrs Jill M Carithers, MSE CCC-SLP | |
Rr 1 Box 185, Ash Flat, AR 72513-9427 | |
(870) 322-8452 | |
Not Available |
Full Name | Mrs Jill M Carithers |
---|---|
Gender | Female |
Speciality | Qualified Speech Language Pathologist |
Experience | 36 Years |
Location | Rr 1 Box 185, Ash Flat, Arkansas |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1396985321 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
235Z00000X | Speech-language Pathologist | 788 (Arkansas) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Gross Therapy Services Inc | 5991072050 | 30 |
News Archive
S*BIO Pte Ltd today announced that the European Commission (EC) has granted orphan drug designation to SB1518, its potent and orally active JAK2 inhibitor for the treatment of primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF). SB1518 has also received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of the same disorder.
Genentech, Inc., a wholly owned member of the Roche Group, today announced that it will present new data for its targeted cancer medicines and the way they may be used in several different cancer types at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Approximately 400 abstracts featuring Genentech and Roche's cancer medicines and investigational agents across 30 cancer types will be presented during the meeting that is taking place June 4 to 8, 2010 in Chicago.
The current pandemic of COVID-19 is caused by the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), a betacoronavirus similar to that which caused the SARS-CoV and MERS-CoV earlier. Scientists are pursuing therapeutic drugs and vaccines to counter the relentless spread of the virus, but so far, none has been established to be effective. However, several are in clinical trials in various parts of the world.
Soumava Sen, D.D.S. is pleased to announce the opening of his state-of-the-art SmileBest Dental & Orthodontics office in Hurst. Dr. Sen is proud to be supported by SmileBest Dental Services, L.L.C., a provider of business and administrative support services and systems to dental practices, including low-exposure digital X-rays, electronic dental records, digital intra-oral cameras and much more.
Pairing a newly developed gel with immunotherapy that was delivered to post-surgical mouse brains with glioblastoma, a highly malignant and deadly cancer, improved the immunotherapy's effectiveness, report researchers from the University of North Carolina Lineberger Comprehensive Cancer Center and colleagues. The findings appeared on Oct. 6, 2021, in Science Advances.
› Verified 1 days ago
Provider Name | Mcbryde Therapy Ops Inc |
---|---|
Provider Type | Part B Supplier - Clinic/group Practice |
Provider Identifiers | NPI Number: 1841324209 PECOS PAC ID: 5395067235 Enrollment ID: O20141204001424 |
News Archive
S*BIO Pte Ltd today announced that the European Commission (EC) has granted orphan drug designation to SB1518, its potent and orally active JAK2 inhibitor for the treatment of primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF). SB1518 has also received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of the same disorder.
Genentech, Inc., a wholly owned member of the Roche Group, today announced that it will present new data for its targeted cancer medicines and the way they may be used in several different cancer types at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Approximately 400 abstracts featuring Genentech and Roche's cancer medicines and investigational agents across 30 cancer types will be presented during the meeting that is taking place June 4 to 8, 2010 in Chicago.
The current pandemic of COVID-19 is caused by the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), a betacoronavirus similar to that which caused the SARS-CoV and MERS-CoV earlier. Scientists are pursuing therapeutic drugs and vaccines to counter the relentless spread of the virus, but so far, none has been established to be effective. However, several are in clinical trials in various parts of the world.
Soumava Sen, D.D.S. is pleased to announce the opening of his state-of-the-art SmileBest Dental & Orthodontics office in Hurst. Dr. Sen is proud to be supported by SmileBest Dental Services, L.L.C., a provider of business and administrative support services and systems to dental practices, including low-exposure digital X-rays, electronic dental records, digital intra-oral cameras and much more.
Pairing a newly developed gel with immunotherapy that was delivered to post-surgical mouse brains with glioblastoma, a highly malignant and deadly cancer, improved the immunotherapy's effectiveness, report researchers from the University of North Carolina Lineberger Comprehensive Cancer Center and colleagues. The findings appeared on Oct. 6, 2021, in Science Advances.
› Verified 1 days ago
Provider Name | Gross Therapy Services Inc |
---|---|
Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
Provider Identifiers | NPI Number: 1033236468 PECOS PAC ID: 5991072050 Enrollment ID: O20170522002316 |
News Archive
S*BIO Pte Ltd today announced that the European Commission (EC) has granted orphan drug designation to SB1518, its potent and orally active JAK2 inhibitor for the treatment of primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF). SB1518 has also received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of the same disorder.
Genentech, Inc., a wholly owned member of the Roche Group, today announced that it will present new data for its targeted cancer medicines and the way they may be used in several different cancer types at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Approximately 400 abstracts featuring Genentech and Roche's cancer medicines and investigational agents across 30 cancer types will be presented during the meeting that is taking place June 4 to 8, 2010 in Chicago.
The current pandemic of COVID-19 is caused by the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), a betacoronavirus similar to that which caused the SARS-CoV and MERS-CoV earlier. Scientists are pursuing therapeutic drugs and vaccines to counter the relentless spread of the virus, but so far, none has been established to be effective. However, several are in clinical trials in various parts of the world.
Soumava Sen, D.D.S. is pleased to announce the opening of his state-of-the-art SmileBest Dental & Orthodontics office in Hurst. Dr. Sen is proud to be supported by SmileBest Dental Services, L.L.C., a provider of business and administrative support services and systems to dental practices, including low-exposure digital X-rays, electronic dental records, digital intra-oral cameras and much more.
Pairing a newly developed gel with immunotherapy that was delivered to post-surgical mouse brains with glioblastoma, a highly malignant and deadly cancer, improved the immunotherapy's effectiveness, report researchers from the University of North Carolina Lineberger Comprehensive Cancer Center and colleagues. The findings appeared on Oct. 6, 2021, in Science Advances.
› Verified 1 days ago
Mailing Address | Practice Location Address |
---|---|
Mrs Jill M Carithers, MSE CCC-SLP Rr 1 Box 185, Ash Flat, AR 72513-9427 Ph: (870) 322-8452 | Mrs Jill M Carithers, MSE CCC-SLP Rr 1 Box 185, Ash Flat, AR 72513-9427 Ph: (870) 322-8452 |
News Archive
S*BIO Pte Ltd today announced that the European Commission (EC) has granted orphan drug designation to SB1518, its potent and orally active JAK2 inhibitor for the treatment of primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF). SB1518 has also received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of the same disorder.
Genentech, Inc., a wholly owned member of the Roche Group, today announced that it will present new data for its targeted cancer medicines and the way they may be used in several different cancer types at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Approximately 400 abstracts featuring Genentech and Roche's cancer medicines and investigational agents across 30 cancer types will be presented during the meeting that is taking place June 4 to 8, 2010 in Chicago.
The current pandemic of COVID-19 is caused by the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), a betacoronavirus similar to that which caused the SARS-CoV and MERS-CoV earlier. Scientists are pursuing therapeutic drugs and vaccines to counter the relentless spread of the virus, but so far, none has been established to be effective. However, several are in clinical trials in various parts of the world.
Soumava Sen, D.D.S. is pleased to announce the opening of his state-of-the-art SmileBest Dental & Orthodontics office in Hurst. Dr. Sen is proud to be supported by SmileBest Dental Services, L.L.C., a provider of business and administrative support services and systems to dental practices, including low-exposure digital X-rays, electronic dental records, digital intra-oral cameras and much more.
Pairing a newly developed gel with immunotherapy that was delivered to post-surgical mouse brains with glioblastoma, a highly malignant and deadly cancer, improved the immunotherapy's effectiveness, report researchers from the University of North Carolina Lineberger Comprehensive Cancer Center and colleagues. The findings appeared on Oct. 6, 2021, in Science Advances.
› Verified 1 days ago
Autumn Treasure Speaight, MCD, CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 75 Highway 62 412 Ste L, Ash Flat, AR 72513 Phone: 870-243-6292 | |
Olivia Louise Taylor, MCD, CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 120 Nix Ridge Rd, Ash Flat, AR 72513 Phone: 870-994-3107 | |
Brittany Wells, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 120 Nix Ridge Rd, Ash Flat, AR 72513 Phone: 870-994-3103 Fax: 870-994-3108 | |
From The Beginning Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 120 Nix Ridge Rd, Ash Flat, AR 72513 Phone: 870-994-3103 | |
Hope Satterwhite, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 120 Nix Rd, Ash Flat, AR 72513 Phone: 870-283-1322 |